Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China · Delayed Price · Currency is CNY 38.50
+0.44 (1.16%)
Jun 2, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 443.24 | 441.75 | 519.74 | 435.93 | 1,894 | 1,811 |
Other Revenue | 6.26 | 6.26 | 39.67 | 6.18 | 7.23 | 7.09 |
| 449.5 | 448.01 | 559.4 | 442.11 | 1,901 | 1,818 | |
Revenue Growth (YoY) | -12.15% | -19.91% | 26.53% | -76.74% | 4.57% | 110.09% |
Cost of Revenue | 247.11 | 247.55 | 286.6 | 269.6 | 940.21 | 705.47 |
Gross Profit | 202.39 | 200.47 | 272.81 | 172.51 | 960.93 | 1,113 |
Selling, General & Admin | 96.36 | 97.64 | 85.9 | 79.21 | 86.09 | 69.63 |
Research & Development | 90.03 | 83.48 | 63.57 | 80.48 | 108.21 | 61.92 |
Other Operating Expenses | 7.13 | 8.26 | 7.05 | 4.95 | 19.49 | 16.84 |
Operating Expenses | 195.07 | 189.25 | 160.05 | 168.31 | 208.2 | 151.61 |
Operating Income | 7.31 | 11.21 | 112.76 | 4.21 | 752.73 | 961 |
Interest Expense | - | - | -0.03 | -0.14 | -0.19 | -0.68 |
Interest & Investment Income | 39.93 | 42.24 | 57.28 | 76.9 | 51.91 | 15.36 |
Currency Exchange Gain (Loss) | -21.85 | -21.85 | 11.44 | 13.07 | 111.92 | -15.48 |
Other Non Operating Income (Expenses) | -19.34 | -0.68 | -1.92 | -0.59 | -1.1 | -0.87 |
EBT Excluding Unusual Items | 6.05 | 30.92 | 179.52 | 93.46 | 915.26 | 959.34 |
Gain (Loss) on Sale of Investments | -0.37 | 0.32 | 0.26 | - | 0.06 | 0.84 |
Gain (Loss) on Sale of Assets | 0.56 | 0.25 | -0.33 | 0 | - | - |
Asset Writedown | -0.66 | -0.04 | - | -6.35 | -18.78 | -0 |
Other Unusual Items | 20.2 | 18.23 | 15.47 | 28.77 | 5.35 | 8.45 |
Pretax Income | 25.79 | 49.68 | 194.92 | 115.88 | 901.9 | 968.63 |
Income Tax Expense | -3.15 | 2.55 | 28.14 | 10.58 | 128.33 | 132.87 |
Earnings From Continuing Operations | 28.94 | 47.13 | 166.78 | 105.3 | 773.56 | 835.76 |
Minority Interest in Earnings | 1.37 | 2.13 | 2.74 | 1.31 | 0.07 | -2.17 |
Net Income | 30.31 | 49.25 | 169.52 | 106.61 | 773.63 | 833.59 |
Net Income to Common | 30.31 | 49.25 | 169.52 | 106.61 | 773.63 | 833.59 |
Net Income Growth | -78.13% | -70.95% | 59.01% | -86.22% | -7.19% | 91.56% |
Shares Outstanding (Basic) | 145 | 145 | 147 | 149 | 149 | 121 |
Shares Outstanding (Diluted) | 145 | 145 | 147 | 149 | 149 | 121 |
Shares Change (YoY) | -1.59% | -1.72% | -1.23% | -0.10% | 23.14% | 8.33% |
EPS (Basic) | 0.21 | 0.34 | 1.15 | 0.71 | 5.18 | 6.87 |
EPS (Diluted) | 0.21 | 0.34 | 1.15 | 0.71 | 5.18 | 6.87 |
EPS Growth | -77.78% | -70.44% | 61.00% | -86.21% | -24.64% | 76.84% |
Free Cash Flow | -81.53 | -23.4 | -116.23 | 74.96 | 524.29 | 707.92 |
Free Cash Flow Per Share | -0.56 | -0.16 | -0.79 | 0.50 | 3.51 | 5.84 |
Dividend Per Share | 0.700 | 0.700 | 1.071 | 0.571 | 1.571 | 2.143 |
Dividend Growth | -34.66% | -34.66% | 87.50% | -63.64% | -26.67% | - |
Gross Margin | 45.02% | 44.75% | 48.77% | 39.02% | 50.54% | 61.20% |
Operating Margin | 1.63% | 2.50% | 20.16% | 0.95% | 39.59% | 52.86% |
Profit Margin | 6.74% | 10.99% | 30.30% | 24.11% | 40.69% | 45.85% |
Free Cash Flow Margin | -18.14% | -5.22% | -20.78% | 16.95% | 27.58% | 38.94% |
EBITDA | 31.97 | 35.19 | 134.03 | 28.88 | 772.63 | 969.2 |
EBITDA Margin | 7.11% | 7.86% | 23.96% | 6.53% | 40.64% | 53.31% |
D&A For EBITDA | 24.66 | 23.98 | 21.27 | 24.68 | 19.9 | 8.2 |
EBIT | 7.31 | 11.21 | 112.76 | 4.21 | 752.73 | 961 |
EBIT Margin | 1.63% | 2.50% | 20.16% | 0.95% | 39.59% | 52.86% |
Effective Tax Rate | - | 5.14% | 14.44% | 9.13% | 14.23% | 13.72% |
Revenue as Reported | 449.5 | 448.01 | 559.4 | 442.11 | 1,901 | 1,818 |
Advertising Expenses | - | 2.91 | 2.82 | 4.21 | 3.19 | 1.63 |